Group items matching

in title, tags, annotations or url

As the new school year approaches parents won't just be in a flurry of buying new pencil cases and the next size up in shoes but also will be looking to stock their cupboard for their health needs for the next year. Along with the Supermarket's Back-to-School sales there is also the opportunity to help parents with a clever display of the top needed cupboard accessories with some smart recommendations to help with choices. Looking at the UK retail market it is also worth considering that we are seeing a push for sustainability in products with those touting green credentials starting to stand out from the competitors but with a backdrop of rising prices making price perhaps more important than ever. Cuts and scrapes One to definitely think about in the children's health range for back to school is plasters and wound cleaning preparations for those inevitable playground grazed knees, cuts and scrapes. With a focus on sustainability and some strong green credentials Elastoplast Green and Protect should be considered for any back to school health display with eco-friendly construction and a climate neutral product but there is also Patch Kids Bamboo Sensitive Plasters which boast being home compostable.

Covid-vaccine maker AstraZeneca said Friday that profits fell sharply in the first half on ballooning costs linked to its takeover of US biotech firm Alexion. The pharmaceutical group added that sales of its Covid-19 vaccine Vaxzevria slumped 49 percent in the second quarter. Net profit slumped 64 per cent to $746 million compared with the first six months of last year, AstraZeneca said in a statement. Operating expenses jumped 33 percent, "reflecting the addition of Alexion, and continued investment in new launches and the pipeline" of drugs, the group said. That offset a 48-percent jump in revenue to more than $22 billion. Revenue rose strongly thanks to sales of Alexion medicines. The group said annual revenue from Covid-19 medicines is anticipated to be broadly flat compared with 2021.

The Taskforce report recognises the important role of community pharmacy and pharmacy teams, and in particular, the fact that they often have most contact with individuals who are receiving medication assisted treatment, commented the Royal Pharmaceutical Society (RPS) on the publication of the Scottish Drug Deaths Taskforce's final report. The final report published on Thursday (June 21) follows four years of work developing and implementing a programme of actions to tackle the rising number of drug deaths in Scotland. RPS, as pharmacy's professional leadership body in Scotland and the rest of Great Britain, has positively engaged with the Taskforce as it carried out its work. Last year, RPS published 'Pharmacy's role in reducing harm and preventing drugs deaths (Scotland)' which contained 14 key recommendations. Many of the recommended actions within the Taskforce's report align with RPS policy.

Eighty-five per cent of adults responding to a survey commissioned by the National Pharmacy Association (NPA) have agreed that community pharmacies are underfunded and that the sector needs more investment to be able to do the work it does. The survey of 1,000+ adults in England was carried out online between August 26 and 30 by an agency called Research Without Barriers (RWB) on behalf of the NPA. Pharmacies in England are now paid less for providing NHS services than they were before the Covid-19 pandemic, after years of real terms cuts. Seventy-four per cent respondents think it's unfair that community pharmacies in England have had no increase in funding for eight years, despite rising business costs. When asked whether it's fair or unfair that pharmacies in England are now paid less for providing NHS services than they were before the pandemic, 81 per cent of people replied that it's unfair.

With GP waiting times on the rise and the secondary NHS care system under pressure, there is a further opportunity for pharmacy to support the general public with self-care. The men's health category is one category where pharmacists can play a leading role - specifically Erection Problems (EPs) where pharmacists can be key to building awareness, destigmatising the condition, and providing support and solutions for the patient. Training for pharmacists is essential - helping them to understand how they can assist those looking for treatment whilst also breaking down barriers and normalising the conversation around EPs. EPs are when a man regularly cannot get and keep an erection. EPs can happen to any adult man, not limited to the older generation, though they are particularly common in men over the age of 40. EPs may happen in some situations over others and so it is increasingly important for men to speak about and identify the cause of their symptoms, particularly because EPs can often be an indication of other serious health conditions like cardiovascular disease, high blood pressure or diabetes. If pharmacies can encourage men to seek help with their EPs, they may also be able to identify additional serious and undiagnosed conditions earlier, thereby supporting men's health more widely.

Many of us know that oral health plays a hugely important role in our general health and wellbeing. We're continuing to see a rise of cosmetic dentistry such as veneers and teeth whitening[1] but fundamentally, it shouldn't be forgotten that oral health encompasses so much more than aesthetics. Our diets, the oral hygiene products we are using, and our brushing techniques are all elements that impact our oral health. It's been hard to miss in the news that there is a dental crisis in the UK, with 'dental deserts' leaving some areas with over 3,000 patients for every NHS dentist[2]. With oral health being of such importance to our overall health[3], it's only reiterated to us at Haleon that we must continue to promote access to dental care and understanding of better dental health. As I've mentioned in previous articles for Pharmacy Business, an understanding of preventative, self-care is hugely beneficial, not just to improve health inclusivity but to help reduce these current burdens on both healthcare and dentistry professionals. We know that at Haleon, we, and the consumer healthcare industry as a whole, have a responsibility to empower people to equip themselves with the tools and information to participate in their own and loved ones' health - and dental health is such an important part of that.

Following the UK government's new pay offer to NHS consultants, the Royal College of Nursing (RCN) wrote to the Health Secretary Victoria Atkins calling for fresh negotiations about nursing pay in England last week. However, the Department of Health and Social Care (DHSC) has rejected their demand, stating that there is no basis to reopen talks as the pay deal was accepted by the NHS Staff Council. In the previous pay deal, nurses were given a one-off payment between £1,655 and £3,789 for 2022/23, and a 5 per cent consolidated pay increase for the 2023/24 financial year. Nursingnotes quoted a DHSC spokesperson as saying: "We hugely value the hard work of NHS nurses and that is why we provided a 5 per cent pay rise. "We also provided two significant non-consolidated awards, which for nurses at the top of Band 5 was over £2,000, equivalent to an extra 6.1 per cent of their basic pay.

Frontline doctors have sounded the alarm over the rising pressure on emergency departments in hospitals across the country as winter virus cases are "creeping up". An average of 234 people were in hospital with flu every day last week, a 53 per cent increase compared to the week before, according to new NHS data. Hospital norovirus cases increased by 15 per cent last week, with an average 406 people hospitalised each day, a 28 per cent increase from the same week last year. Measures to stop the spread of norovirus to other patients led to the closure of an average of 92 beds were closed each day last week.

Community Pharmacy England (CPE) Chief Executive, Janet Morrison met with the new Pharmacy Minister, Dame Andrea Leadsom MP this week and discussed a range of critical topics, including funding and pressures. Janet informed the minister that community pharmacies continue to face immense financial pressures, and highlighted the need for an improved core contract. She told the minister that 35-50 per cent real term cuts and rising costs have led to closures, consolidations and cashflow. This has weakened the capacity for the network to respond to displaced patients, increased risk in terms of the safety of medicine supply, and led to loss of service for communities in the most deprived areas, she said.

The British Generic Manufacturers Association (BGMA) has warned that England's 42 integrated care boards (ICBs) may need to allocate an extra £37 million from their budgets annually for the next five years due to the spiralling tax rates. The government's Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) rebate rate increased more than five-fold in the past two years, the BGMA said in its white paper released on Monday (October 30). The report, conducted by consultancy firm Conclusio in consultation with local NHS leaders, examined the potential effects of the VPAS on ICB budgets. BGMA said that due to the elevated VPAS rate, each ICB in England will experience significant increases in expenses for branded generics and biosimilars annually - a consequence of reduced competition.

The Medicines and Healthcare products Regulatory Agency (MHRA) has reminded healthcare professionals prescribing aripiprazole to alert patients about its possible side effects, following a rise in the number of reports of gambling disorder associated with the drug. Patients taking aripiprazole, which is used for the treatment of schizophrenia and bipolar disorder, are at risk of developing unusual urges or cravings that they cannot resist, including behaviours such as addictive gambling, excessive eating or spending, or an abnormally high sex drive. The regulator has received 69 reports of gambling or gambling disorder suspected to be caused by aripiprazole in the last 14 years via the Yellow Card Scheme, out of which 32 were received between 1 January and 31 August this year. Alison Cave, MHRA Chief Safety Officer, said: "The number of reports for suspected gambling and other impulsive behaviours associated with aripiprazole are small in comparison to the frequency with which it is prescribed, but the consequences for any patient developing these conditions can be significant."

Nexium Control, the UK's number one selling heartburn product for 24-hour protection1, has commissioned research to explore consumer attitudes to heartburn awareness of the different products on the market in Great Britain and Ireland (1,500 UK and 500 IE respondents). The research found that 53% of respondents usually opt for short-acting treatments to heartburn2, despite longer-acting products being able to provide relief over a 24-hour period. The research from Nexium Control revealed that 54% of people surveyed wished there was a product that managed symptoms for longer3, with 55% of respondents agreeing that short-acting treatments only last a maximum of five hours4. To help their patients understand there are longer-acting options available, pharmacists can provide information and guidance on treatments, such as proton pump inhibitors like Nexium Control. Shorter-acting products, which shoppers often reach for, work by either neutralising the acid already in the stomach or by forming a layer that floats to the top of the stomach, stopping acid rising into the food pipe. Double action treatments which utilise both methods are also available. Containing esomeprazole, Nexium Control reduces the production of stomach acid for up to 24-hour protection with just one pill, treating the cause and symptoms of heartburn - allowing time for the oesophagus to recover from the acid irritation.

People infected with monkeypox can isolate at home if they remain well enough, whilst following measures to limit close contact with others, the UK's health security agency (UKHSA) said on Monday (May 30), part of guidance designed to curb the country's rise in cases of the viral illness. More than 300 suspected and confirmed cases of monkeypox have been reported in May, outside of Africa where the virus is endemic. The usually mild illness spreads through close contact and can cause flu-like symptoms and pus-filled skin lesions. An additional 71 cases of monkeypox have been identified in England, taking the total number of confirmed cases in the UK as a whole to 179 since early May. Scientists are looking into what might explain the unusual surge of cases, given most are not linked to travel. The UKHSA indicated community transmission was occurring in the UK and said infected people should avoid contact with others until their lesions have healed and the scabs have dried off.

The NHS is facing a range of long term challenges which needs to be countered with prevention, enhance personalised care and sustainable performance, health and social care secretary Sajid Javid said on Tuesday (March 8). In his speech on healthcare reform at the Royal College of Physicians in London, he said: "We face some long-term challenges: how to keep the NHS focused on delivery while futureproofing it for changing demographics and disease; how to meet rising patient expectations and address the injustices of widespread disparities; and how to deal with an unsustainable financial trajectory while backing the brilliant people who work in health and care." Javid emphasised on three key points for healthcare reform - prevention, personalisation and performance. He said, prevention is not just about building a 'national hospital service' but a true 'National Health Service'.

Two new subvariants of Omicron - BA.4 and BA.5 - are spreading much faster than other corovanirus variants in Europe, which could lead to more hospitalisations and deaths as they become dominant, the EU's disease prevention agency said on Monday (June 13). Most EU countries have so far detected low rates of the two subgroups. But in countries where the proportion has risen - such as Portugal, where BA.5 accounted for 87 per cent of cases by May 30 - there have been surges in overall cases, according to the European Centre for Disease Prevention and Control (ECDC). The two sublineages were added to the World Health Organization's monitoring list in March and have also been designated as variants of concern by the ECDC. Variants BA.4 and BA.5 do not appear to carry a higher risk of severe disease than other forms of Omicron.But an increase in case numbers from higher transmission rates risks leading to an increase in hospitalisations and deaths, the agency said. "The growth advantage reported for BA.4 and BA.5 suggest that these variants will become dominant," ECDC said in a statement on its website.

Britain's billionaire Issa brothers and Indian tycoon Mukesh Ambani are preparing to face off in the final battle for Boots UK ownership, according to Bloomberg. In the first round, Issa brothers have submitted the highest offer, the people with knowledge of the matter told Bloomberg. "The brothers are going up against Ambani, who's been working on a bid together with buyout firm Apollo Global Management Inc." The source said: "Bidders are now sizing up Boots' billions in pension guarantees - which they'll have to take on - as they figure out how much they can pay for the business." They're also working around the clock to arrange financing in a difficult market, which has gotten that much tougher due to the war in Ukraine, soaring inflation and rising interest rates, according to the people.

When Ignasi Biosca-Reig heard there were shortages of amoxicillin in Spain, he quickly added shifts at his drug company's factories to boost production of the popular antibiotic. But a few extra shifts was as far as he could go. Much as he would have liked to significantly increase supplies, Biosca-Reig said he couldn't justify investing millions of euros in new production lines unless he was paid more for the generic drug to cover sharply rising costs. But, like many other European countries, Spain set the price manufacturers are paid for paediatric amoxicillin when the generic version of the drug was first launched in the country two decades ago, and it has barely budged since. "It's a non-business," said Biosca-Reig, chief executive of Spanish drugmaker Reig Jofre. "We wanted to react, but we had a problem," he said. "The costs go up, the price remains the same."

Thousands of lung cancer patients in England will benefit from a ground-breaking new drug that can reduce the risk of relapse. This follows a deal brokered by NHS England and approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for atezolizumab therapy to treat non-small cell lung cancer (NSCLC). More than 850 patients are expected to be eligible for the drug in the first year, rising to more than 1000 in the third year. It is the first immunotherapy approved for patients with early-stage NSCLC who have undergone surgery and chemotherapy. Clinical trials have shown that atezolizumab can reduce the risk of cancer relapse or death by 34 per cent in patients with early-stage NSCLC.

Dry eye disease, also known as dry eye syndrome, occurs when the eye stops producing enough tears, the tears that are made are of poor quality or the tears evaporate faster than they should. This causes dryness and irritation of the surface of the eye and results in inflammation, discomfort, and damage.[i] Symptoms include dry, red, itchy or tired eyes, blurred vision and foreign body sensation. From over-the-counter eye drops and heated eye masks, to eyelid-cleansing wipes, there are a multitude of options that can be offered to sufferers to provide relief. As a result of the pandemic and new living and working patterns, the World Health Organization has indicated dry eye disease is on the rise. This can be attributed to various lifestyle factors including increased screen use and wearing of face masks. An increase in sufferers seeking advice on the condition in pharmacies has also been reported. It is no surprise that sufferers will turn to their pharmacists for help, support and information on the condition and how it can be managed by treatment options available over-the-counter.

Pfizer's oral Covid-19 therapy will be evaluated as a potential treatment for patients hospitalised with the illness in a major British trial, scientists said on Monday, as cases rise in some parts of the world. The world's largest randomised study of potential medicines for Covid-19, dubbed the RECOVERY trial, will assess Paxlovid across hospitals in Britain, which has already approved the drug for early-stage treatment. "Paxlovid is a promising oral antiviral drug but we don't know if it can improve survival of patients with severe Covid-19," said Peter Horby, a professor at the University of Oxford and joint chief investigator of the RECOVERY trial. The scientists said they aim to mainly find whether Pfizer's Paxlovid reduces the risk of death among patients admitted to hospitals with Covid-19.